Assessments | Treatment Period | ||||||
---|---|---|---|---|---|---|---|
Screening1 | Randomization | Baseline | 4 Months | 8 Months | 12 Months | End of study visit | |
Informed consent | X | ||||||
Inclusion/exclusion criteria | X | ||||||
Relevant medical history | X | ||||||
Prior medication/therapy of current CRC | X | ||||||
Physical exam, vital signs and ECOG performance status | X | X | X | X | X | X | |
Hematology, biochemistry, and coagulation profile | X2 | X2 | X2 | X2 | X2 | ||
Randomization | X | ||||||
Blood collection for biological assessment | X | X | |||||
Blood collection for TxB2/metformin quantification3 | X | X | X | X | |||
Feces collection4 | X | X | |||||
Questionnaires (FACIT, HADS, Distress, IPAQ, and EPIC [4]) | X | X | |||||
Colonoscopy and biopsies | X5 | X5 | |||||
Adverse events | X6 | X | X | X | X | X | |
Concomitant medication | X | X | X | X | |||
Study treatment supply | X | X | X | ||||
Compliance (via pill count) | X | X | X |